In advanced epithelial ovarian cancer (AEOC) patients, the standard of care is primary debulking surgery (PDS), aimed to reach completeness of cytoreduction, followed by first-line chemotherapy with carboplatin and paclitaxel. For patients in stage IIIC/IV that are not ideal candidates for PDS, the treatment that has recently gained acceptance is a combination of neoadjuvantchemotherapy followed by interval debulking surgery (IDS)